JPMorgan says this biotech stock can more than double following steep declines

JPMorgan initiated coverage of Neurogene at Overweight with a $60 price target, implying 132% upside from Wednesday’s close, and identified 2027 trial data for its Rett syndrome gene therapy NGN-401 as a potential catalyst. Shares have fallen about 32% over three months; the company also reported softer-than-expected Q2 results and higher R&D costs. JPMorgan’s call is in line with consensus, with all 10 covering analysts rated Buy or Strong Buy, according to LSEG.

Analysis

The bullish setup is unusually dependent on a distant clinical readout: absent nearer-term efficacy or safety evidence, an analyst target is not a catalyst that resolves the core binary risk. With every covering analyst already positive, the call adds little diversification to the bull case and may leave sentiment vulnerable to any safety concern, trial delay, or weaker-than-expected update. The less visible risk is funding optionality: rising R&D costs can increase the chance that future development is funded through equity, but current cash, burn rate, and runway are not provided, so dilution risk cannot be quantified. In the next 1–3 months, watch for company updates and changes to cash/runway rather than assuming a clinical rerating. Over a 6–18 month horizon, trial execution and safety will matter more than the broad biotech rebound; the cited 2027 data catalyst is beyond that window. A broad biotech proxy such as XBI can help isolate sector beta, but a direct pair trade is not justified without valuation, cash, and clinical details.

Key Decisions for Investors

• No immediate directional position: treat the bullish analyst view as sentiment support, not independent validation of NGN-401.
• Before considering a long, verify cash and quarterly burn, expected runway, trial enrollment and timing, and whether any interim safety or efficacy data are planned before 2027.
• If already long, size for a binary clinical asset and define an exit trigger around a trial delay, material safety signal, or a meaningful deterioration in cash runway; avoid relying on the $60 target as a downside floor.
• Falsification of the cautious stance would be credible, company-reported clinical evidence that supports efficacy without a concerning safety profile, alongside runway adequate to reach the next major readout.